Loss of heterozygosity alterations associated with progesterone therapy in endometrial hyperplasia and adenocarcinoma

Autor: R. Y. Osamura, Takao Shinozuka, Masaru Murakami, Toshihiro Miyamoto, T. Yoshitake, Toshinari Muramatsu, Susumu Takekoshi, Masanori Yasuda, S. Kotajima, Hiroshi Kajiwara
Rok vydání: 2005
Předmět:
Zdroj: International Journal of Gynecological Cancer. 15:155-162
ISSN: 1525-1438
1048-891X
DOI: 10.1111/j.1048-891x.2005.14423.x
Popis: Loss of heterozygosity (LOH) was analyzed in four patients with endometrial hyperplasia (EH) with atypia (two patients) and without atypia (two patients) and in five patients with endometrial adenocarcinoma (EAC) to clarify the clinicopathologic relationship between genetic alterations and hormone therapy. Each patient was initially administered high-dose medroxyprogesterone acetate (MPA) as a uterine-sparing treatment. The five microsatellite markers used to analyze LOH were at chromosomal loci 8p22.1, 8p21, 8p21.3, 8p22, and 8p22. DNA was extracted from paraffin-embedded sections before, during, and after MPA therapy using laser capture microdissection. As a result, LOH was more frequently detected after MPA therapy (overall ratios were 16, 17, and 29% before, during, and after MPA therapy, respectively). LOH is more easily detected in EH loci than in EAC loci before MPA. For EAC, initial LOH detection on chromosome 8 may be related to an incomplete response to MPA, but negative LOH does not guarantee a favorable treatment outcome. For EH or atypical endometrial hyperplasia, it is unknown whether LOH alteration associated with MPA therapy is related to atypia of the disease.
Databáze: OpenAIRE
Externí odkaz: